Clinical trials: Breast Tumor Tissue
Solid Tumor, Adult, Breast Cancer
Study on Skin Toxicities Induced by Cancer Treatments
The skin toxicities will be evaluated on patient (male or female) with an indication of cancer treatment in the case of solid tumor of the breast, or lung.
- Conditions
- Solid Tumor, Adult, Breast Cancer, Lung Cancer
- Trial name
- DERMACLIC (NCT04402606)
- Testing
- Evaluation on skin toxicities
- Where
- France
- Volunteers
- 292 people
- Sponsor
- Institut Curie
Breast Cancer
Sodium (23Na) MRI for Tumour Characterisation and Assessment of Therapy Response in Breast Cancer
The scope of this study is the methodological development and optimisation of sodium MRI (23Na-MRI) protocols for breast cancer imaging.
- Trial name
- NaRNIA (NCT03940092)
- Testing
- MRI, PET/MRI
- Where
- United Kingdom
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Breast Cancer Lymphedema, Post-Mastectomy Secondary Lymphedema
New Therapeutic Approach in Upper Limb Lymphedema Secondary to Breast Cancer: Activity-oriented Proprioceptive Antiedema Therapy (TAPA)
This study evaluates the effectiveness of an experimental proposal therapy for upper limb lymphedema secondary to breast called Activity-oriented proprioceptive antiedema therapy (TAPA) facing the consensual gold standard…
- Trial name
- NCT03762044
- Testing
- Activity-oriented Proprioceptive Antiedema Therapy (TAPA), Complete Decongestive Therapy (CDT)
- Where
- Spain
- Volunteers
- 51 people
- Sponsor
- Hospital Universitario Reina Sofia de Cordoba
Breast Cancer, Lymphoma
A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms
This is a dosage escalation study to estimate the maximum tolerated dose of staurosporine analogue UCN-01. Groups of 3 to 6 patients receive a 72-hours intravenous continuous infusions of UCN-01 from day 1 to day 4 of each cycle…
- Conditions
- Breast Cancer, Lymphoma, Neoplasm, Prostatic Neoplasm
- Trial name
- NCT00001444
- Testing
- 7-hydroxystaurosporine (UCN-01)
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Nurse-Delivered Adapted MBSR During Breast Cancer Radiotherapy
This randomized study examined whether adding a condensed mindfulness programme to standard radiotherapy care could improve psychosocial outcomes among women treated for breast cancer.
- Trial name
- NCT06025799
- Testing
- Adapted mindfulness-based stress reduction
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Alexandria University
Breast Density, Body Composition
Chilean Maternal & Infant Cohort Study II (CHiMINCs-II)
The Chilean Maternal \& Infant Cohort Study II (ChiMINCs II) is an ongoing cohort that is part of the Chilean Maternal and Infant Nutrition Observatory of the South-East area of Santiago, Chile.
- Conditions
- Breast Density, Body Composition, Nutritional Status, Mental Health Issue
- Trial name
- CHiMINCs-II (NCT03920098)
- Testing
- Nutrition and mental health during pregnancy
- Where
- Chile
- Volunteers
- 1,927 people, healthy volunteers welcome
- Sponsor
- Instituto de Nutrición y Tecnología de los Alimentos
Breast Neoplasms
Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients
Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788) is an antibody-conjugated drug.
- Trial name
- NCT04983121
- Testing
- Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shengjing Hospital
Breast Neoplasms
Boost Use in Breast Conservation Radiotherapy
This is a two arm randomized study for patients who are undergoing radiotherapy following breast conservation surgery for breast cancer.
- Trial name
- NCT00138814
- Testing
- Radiotherapy (boost versus no boost)
- Where
- 3 sites in Australia
- Volunteers
- 680 people
- Sponsor
- St George Hospital, Australia
DCIS
Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery
This is a feasibility study which will evaluate the effects of pre-operative treatment of DCIS of the breast with palbociclib. Patients with biopsy-proven DCIS are eligible for the study.
- Trial name
- WI223281 (NCT03535506)
- Testing
- Palbociclib
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Georgetown University
Early and Locally Advanced Breast Cancer
ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness
The goal of this performance study is to learn if treatment with neoadjuvant endocrine therapy compared to chemotherapy has comparable efficacy, but better quality of life outcomes in endocrine responsive participants with early…
- Trial name
- TEODOR (NCT07084558)
- Testing
- blood sample for Signatera (TM) test, biopsy for Ki-67 assessment, FFPE tumor sample for Signatera (TM) test (archived)
- Where
- 14 sites in Austria
- Volunteers
- 350 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Breast Cancer
Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease
RATIONALE: Collecting and storing samples of blood and tumor tissue from patients with cancer to test in the laboratory may help the study of cancer in the future.
- Trial name
- NCT00898508
- Testing
- gene expression analysis, mutation analysis, proteomic profiling
- Where
- 3 sites in United States
- Volunteers
- 563 people
- Sponsor
- City of Hope Medical Center
Breast Cancer
A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early
Patients with localized primary breast cancer including inflammatory breast cancer suitable for primary medical treatment and/or regional lymph node metastases receive six cycles of chemotherapy with epirubicin and docetaxel.
- Trial name
- PROMIX (NCT00957125)
- Testing
- Epirubicin, Docetaxel, Bevacizumab
- Where
- 6 sites in Sweden
- Volunteers
- 151 people
- Sponsor
- Thomas Hatschek
Advanced Solid Tumors
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
Researchers are looking for a better way to treat people who have advanced solid tumors. Advanced solid tumors are solid cancers that may have spread to nearby tissue, lymph nodes and/or to distant parts of the body and that are…
- Trial name
- NCT05537740
- Testing
- BAY3375968, Pembrolizumab
- Where
- 26 sites in United States, Belgium and 6 more
- Volunteers
- 129 people
- Sponsor
- Bayer
Breast Cancer, Ovarian Cancer
Intermittent Fasting Accompanying Chemotherapy in Gynecological Cancers
The aim of this trial is an evaluation of the effectiveness of intermittent fasting as a supplementary therapy in patients with breast cancer and ovarian cancer in respect to quality of life, reduction of side effects and…
- Trial name
- FIT2 (NCT03162289)
- Testing
- Fasting, Vegan
- Where
- 8 sites in Germany
- Volunteers
- 150 people
- Sponsor
- Charite University, Berlin, Germany
Breast Cancer, HER2 + Breast Cancer
Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.
The aim of this study is to evaluate the efficacy and safety of TQB2102 compared to TCbHP in the neoadjuvant treatment of HER2-positive breast cancer.
- Trial name
- NCT07136974
- Testing
- TQB2102, Docetaxel + Carboplatin + Trastuzumab +Pertuzumab
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Henan Cancer Hospital
Early Breast Cancer
Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer
This is a multicenter, open-label, single-arm, one-stage, phase II study to assess the efficacy of a chemotherapy-free pathological complete response (pCR)-guided strategy with trastuzumab and pertuzumab (given as a subcutaneous…
- Trial name
- PHERGAIN-2 (NCT04733118)
- Testing
- Trastuzumab and Pertuzumab (FDC SC) and T-DM1
- Where
- 41 sites in Bulgaria, Germany and 3 more
- Volunteers
- 393 people
- Sponsor
- MedSIR
Breast Cancer
IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry
This is a prospective, registry trial which will enroll women aged 65 and above with early stage, low risk breast cancer who will be treated with partial mastectomy and intraoperative radiation therapy (IORT).
- Trial name
- NCT03536897
- Testing
- IORT
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- Mount Carmel Health System
Breast Cancer
PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer
Non-randomized, open label, multicentric translational research study in women with untreated invasive breast carcinoma eligible for primary surgery (Stage I-IIIA).
- Trial name
- PAMELA (NCT01973660)
- Testing
- Lapatinib, Trastuzumab, Endocrine Therapy
- Where
- 22 sites in Spain
- Volunteers
- 151 people
- Sponsor
- SOLTI Breast Cancer Research Group
Breast Cancer Female
Does Type of Anesthesia Influence Inflammation Change After Breast Surgery?
The Neutrophil to Lymphocyte Ratio (NLR) is a frequently used biomarker of the systemic inflammatory response and is considered one of the most sensitive markers of inflammation.
- Trial name
- NCT04172220
- Testing
- Midazolam, PECS, Opioid-free general anesthesia
- Where
- Italy
- Volunteers
- 68 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Breast Carcinoma, Male Breast Carcinoma
Access to Genetic Testing in Underserved Patients With Cancer
This study compares the experiences of people who receive information about genetic testing from a computer-generated character to patients who receive information from a human genetics healthcare provider.
- Conditions
- Breast Carcinoma, Male Breast Carcinoma, Malignant Solid Neoplasm, Metastatic Prostate Carcinoma
- Trial name
- NCT06422455
- Testing
- Best Practice, Educational Intervention, Electronic Health Record Review
- Where
- 2 sites in United States
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- University of Southern California
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.